UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 183

Sortiert nach

Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung

Chest, 2017-05, Vol.151 (5), p.1141-1146

Wolin, Edward M., MD

2017

Volltextzugriff (PDF)

PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors

Cancer letters, 2013-07, Vol.335 (1), p.1-8

Wolin, Edward M

2013

Volltextzugriff (PDF)

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

The New England journal of medicine, 2014-07, Vol.371 (3), p.224-233

2014

Volltextzugriff (PDF)

Challenges in the Diagnosis and Management of Well‐Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations

The oncologist (Dayton, Ohio), 2015-10, Vol.20 (10), p.1123-1131

Wolin, Edward M.

2015

Volltextzugriff (PDF)

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

The Lancet (British edition), 2011-12, Vol.378 (9808), p.2005-2012

2011

Volltextzugriff (PDF)

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

Endocrine-related cancer, 2016-03, Vol.23 (3), p.191-199

2016

Volltextzugriff (PDF)

Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review

Oncology, 2019-06, Vol.96 (6), p.273-289

2019

Volltextzugriff (PDF)

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518

Journal of clinical oncology, 2017-05, Vol.35 (15), p.1695-1703

2017

Volltextzugriff (PDF)

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

The New England journal of medicine, 2011-02, Vol.364 (6), p.514-523

2011

Volltextzugriff (PDF)

Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis

Cancer science, 2018-01, Vol.109 (1), p.174-181

2018

Volltextzugriff (PDF)

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Endocrine practice, 2016-09, Vol.22 (9), p.1068-1080

2016

Volltextzugriff (PDF)

Consensus on biomarkers for neuroendocrine tumour disease

The lancet oncology, 2015-09, Vol.16 (9), p.e435-e446

2015

Volltextzugriff (PDF)

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Drug design, development and therapy, 2015-01, Vol.9 (default), p.5075-5086

2015

Volltextzugriff (PDF)

Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study

Chest, 2013-04, Vol.143 (4), p.955-962

2013

Volltextzugriff (PDF)

Multifocality in Small Bowel Neuroendocrine Tumors

Journal of gastrointestinal surgery, 2018-02, Vol.22 (2), p.303-309

2018

Volltextzugriff (PDF)

Resection Prolongs Overall Survival for Nonmetastatic Midgut Small Bowel Neuroendocrine Tumors: A National Cancer Data Base Study

Pancreas, 2022-02, Vol.51 (2), p.171

2022

Volltextzugriff (PDF)

Real-world approaches for extending progression-free survival in patients with metastatic pancreatic neuroendocrine tumors: focus on timing, sequencing, regimen initiation, and maintenance strategies using somatostatin analogs, targeted agents, and peptide receptor radiotherapy

Clinical advances in hematology & oncology, 2018-09, Vol.16 Suppl 17 (9), p.11-14

Wolin, Edward M

2018

Volltextzugriff (PDF)

Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States

Pancreas, 2017-05, Vol.46 (5), p.639-647

2017

Volltextzugriff (PDF)

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study

Endocrine, 2021-02, Vol.71 (2), p.502-513

2021

Volltextzugriff (PDF)

The expanding role of somatostatin analogs in the management of neuroendocrine tumors

Gastrointestinal cancer research, 2012-09, Vol.5 (5), p.161-168

Wolin, Edward M

2012

Volltextzugriff (PDF)

Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)

Endocrine-related cancer, 2022-06, Vol.29 (6), p.335-344

2022

Volltextzugriff (PDF)

Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment

Clinical nuclear medicine, 2017-06, Vol.42 (6), p.436-443

2017

Volltextzugriff (PDF)

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms

PloS one, 2019-09, Vol.14 (9), p.e0221994-e0221994

2019

Volltextzugriff (PDF)

Patient‐Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo‐Controlled, Double‐Blind and 32‐Week Open‐Label Study

The oncologist (Dayton, Ohio), 2018-01, Vol.23 (1), p.16-24

2018

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(170)
Mit Volltextzugriff
(164)

Publikationsform

Sprache

Englisch
(183)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

Science & Technology
(70)
Life Sciences & Biomedicine
(69)
Humans
(60)
Male
(49)
Female
(43)
Middle Aged
(41)
Aged
(36)
Neuroendocrine Tumors
(30)
Oncology
(30)
Adult
(27)
Tumors
(25)
Neuroendocrine Tumors - Drug Therapy
(21)
Patients
(20)
Aged, 80 And Over
(19)
Metastasis
(19)
Treatment Outcome
(17)
Somatostatin - Analogs & Derivatives
(15)
Antineoplastic Agents - Therapeutic Use
(14)
Double-Blind Method
(14)
Neuroendocrine Tumors - Pathology
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung

PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

Challenges in the Diagnosis and Management of Well‐Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Consensus on biomarkers for neuroendocrine tumour disease

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study

Multifocality in Small Bowel Neuroendocrine Tumors

Resection Prolongs Overall Survival for Nonmetastatic Midgut Small Bowel Neuroendocrine Tumors: A National Cancer Data Base Study

Real-world approaches for extending progression-free survival in patients with metastatic pancreatic neuroendocrine tumors: focus on timing, sequencing, regimen initiation, and maintenance strategies using somatostatin analogs, targeted agents, and peptide receptor radiotherapy

Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study

The expanding role of somatostatin analogs in the management of neuroendocrine tumors

Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)

Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms

Patient‐Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo‐Controlled, Double‐Blind and 32‐Week Open‐Label Study

Suchergebnisse filtern